2025-10-11 - Analysis Report
Okay, here's the analysis of TEM (Unknown Company) based on the data provided, formatted as requested.

## TEM (Unknown Company) Analysis

**Company Overview:** Unknown Company, ticker TEM, operates in an unspecified industry.

### 1. Performance vs. S&P 500 (VOO)

*   **TEM Cumulative Return:** 56.98%
*   **VOO Cumulative Return:** 28.30%
*   **Absolute Divergence:** 36.6%
*   **Relative Divergence:** 67.1%

**Analysis:** TEM has significantly outperformed the S&P 500 (VOO) over the analyzed period. The relative divergence of 67.1% indicates that TEM's outperformance is substantial, placing it in the higher end of its historical divergence range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2023-2025  | 57.0%  | 70.1% | 30.0%  | 0.3  | 17.0   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** 57.0% indicates very high growth over the period.
*   **MDD (Maximum Drawdown):** 70.1% is a very high drawdown, suggesting significant volatility and risk.
*   **Alpha:** 30.0% is a high alpha, indicating significant outperformance relative to the market.
*   **Beta:** 0.3 is a low beta, suggesting that the stock is less sensitive to market movements than the overall market.
*   **Cap(B):** $17 Billion Market Cap

### 2. Recent Price Action

*   **Current Price:** 97.99
*   **Last Market Data:** Price: 98.05, Previous Close: 99.28, Change: -1.24
*   **5-day Moving Average:** 95.798
*   **20-day Moving Average:** 86.9298
*   **60-day Moving Average:** 74.8537

**Analysis:** The price closed at 97.99, with the last market data showing a small price drop. The stock price is above all its moving averages (5, 20, and 60-day), indicating an uptrend, but the recent drop from the previous close suggests a slight pullback.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 61.54 (Not overbought or oversold)
*   **PPO:** 1.4166 (Positive, indicating an uptrend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (11 shares - Very Safe - MRI:0.90) (Cash Ratio: 0% on 2025-10-03) - Strong Buy Signal
*   **Recent (20-day) Relative Divergence Change:** 19.9 (+) - Short-term upward momentum.
*   **Expected Return (%):** NaN - Insufficient data to project long-term outperformance.

**Analysis:**

*   The MRI suggests the stock is in a favorable investment range (high recommendation).
*   RSI is neutral, meaning the stock isn't overbought or oversold.
*   The PPO is positive, confirming the upward trend suggested by the moving averages.
*   The change of -1.24 from the previous close, indicates a minor downturn.
*   The significant uptick in relative divergence over the last 20 days suggests increasing outperformance.
*   However, the "Expected Return" being NaN indicates a lack of reliable data to project its future outperformance against the S&P 500.

### 4. Recent News & Significant Events (Yahoo Finance)

*   **[2025-10-09]** Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy (Business Wire)
*   **[2025-10-08]** Tempus AI, Inc. (TEM): A Bull Case Theory (Insider Monkey)
*   **[2025-10-05]** Tempus AI, Inc. (TEM) Secures FDA Clearance for xR IVD Device to Enhance Drug Discovery (Insider Monkey)
*   **[2025-10-01]** Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density (Business Wire)
*   **[2025-09-29]** Tempus AI (TEM): Assessing Valuation as Investor Interest Grows Without Clear Catalysts (Simply Wall St.)
*   **[2025-09-26]** TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now? (Zacks)

**Analysis:** Recent news is generally positive. Highlights include:

*   Selection for the ARPA-H ADAPT program.
*   FDA Clearance.
*   Bullish articles.
*   However, one article notes that investor interest is growing without clear catalysts, and another compares TEM's valuation against competitors. This suggests that while the news is mostly positive, valuation concerns might exist.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 2.15 (Buy)
*   **Number of Opinions:** 11
*   **Target Price:**
    *   Average: 77.55
    *   High: 100.00
    *   Low: 60.00
*   **Recent Rating Changes:** No changes recorded

**Analysis:** Analyst consensus is a "Buy" with a mean rating indicating a generally positive outlook. The average target price is below the current price, which might suggest that analysts believe the stock is currently overvalued.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 예상 EPS |
|------------|-------|----------|
| 2025-08-08 | -0.22 | -0.22988 |
| 2025-05-06 | -0.24 | -0.26003 |
| 2025-02-24 | -0.18 | -0.15    |
| 2024-11-04 | -0.25 | -0.26608 |
| 2024-08-06 | -0.63 | -0.59    |

**Analysis:** The company is consistently reporting negative EPS (Earnings Per Share), though it often beats expectations. This indicates that while the company is not yet profitable, it is performing better than anticipated. The EPS losses seem to be narrowing over time, which could be a positive sign.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.31B   | 61.99%        |
| 2025-03-31 | $0.26B   | 60.69%        |
| 2024-12-31 | $0.20B   | 60.83%        |
| 2024-09-30 | $0.18B   | 58.50%        |
| 2024-06-30 | $0.17B   | 45.50%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-06-30 | $0.31B   | -13.84%   |
| 2025-03-31 | $0.33B   | -20.86%   |
| 2024-12-31 | $0.06B   | -23.10%   |
| 2024-09-30 | $0.05B   | -141.16%  |
| 2024-06-30 | $0.10B   | -562.04%  |

**Analysis:**

*   **Revenue:** Revenue is consistently growing.
*   **Profit Margin:** Profit margins are very high and stable (around 60%), suggesting a strong business model.
*   **Equity:** Equity levels are fluctuating.
*   **ROE (Return on Equity):** ROE is significantly negative, indicating that the company is not generating profits relative to its equity. Although it has improved quite a bit.

### 7. Overall Summary

TEM (Unknown Company) exhibits strong growth and has significantly outperformed the S&P 500. Recent news is largely positive, with the company securing contracts and FDA clearance. However, the company is currently unprofitable (negative EPS and ROE), though revenue and profit margins are growing. Analyst consensus is a "Buy," but average target prices are below the current price, which may indicate overvaluation concerns. The high MDD (70.1%) highlights the potential for significant price swings.

**Investment Recommendation:** The MRI suggests a high investment recommendation, but potential investors should be aware of the risks associated with an unprofitable company, valuation concerns, and high volatility. A more detailed analysis of the company's business model, competitive landscape, and long-term growth prospects is recommended before making an investment decision.
